• Monika Proczko, Sjaak Pouwels, Lukasz Kaska, and Pieter S Stepaniak.
• Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland.
• Obes Surg. 2019 Apr 1; 29 (4): 1142-1147.

BackgroundIn 2015 our hospital implemented the ERABS protocol. From that moment also morbidly obese patients with end-stage renal disease (ESRD) were enrolled. The objective of this study was to evaluate the potential benefits and safety of the ERABS protocol for ESRD morbidly obese patients compared with patients who are morbidly obese patients undergoing bariatric surgery.MethodsA retrospective review of a prospectively collected database was conducted for ESRD patients who underwent bariatric surgery according to the ERABS protocol. The primary endpoint was the length of hospital stay in days. Secondary endpoints were the number of re-admissions, re-operations, length of renal replacement therapy, and complications during admission and within 30 days after surgery. Propensity score matching was used to compare groups.ResultsFrom 2015 onward 1199 non-ESRD patients and 21 with ESRD were operated. Propensity score matching resulted in two groups of 19 patients. In terms of comorbidities, both groups presented typical components of metabolic syndrome. In the ESRD group, one patient had serious complications (rated as Clavien-Dindo IIIb and IVb) at the first postoperative day after OAGB. The overall complication rate was comparable and not significantly different compared with the non-ESRD group.ConclusionOur study shows that ERAS in this population has overall minimal adverse events and lack of any ERAS-related complications.

34 keywords...

hide…